Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.Real-Time EquityWire is available only to registered users. This is best for professional traders and people who track markets actively.
Pricing pressure in North America--particularly the US--is likely to weigh on the performance of Dr Reddy's Laboratories Ltd. for the June quarter, analysts said. Price erosion in the generic version of cancer drug Revlimid, a key contributor to past profitability, and intense competition in other existing portfolio are expected to result in weaker sales in the US. However, steady growth in domestic sales may provide support to overall earnings.
Share this Story:
